Are Guidelines Worth the Cost?
A thoughtful perspective on the purpose, focus and cost of guideline efforts in rheumatology has been published in the journal Rheumatology.
A thoughtful perspective on the purpose, focus and cost of guideline efforts in rheumatology has been published in the journal Rheumatology.
Reuters and the Wall Street Journal have reported that the largest U.S. pharmacy benefit managers (PBM) of private prescription drug benefits have cut off at least eight pharmacies that work closely with drugmakers, intensifying scrutiny of a system that helps inflate drug prices.
Psoriasis and psoriatic arthritis patient have significantly higher rates of comorbidity, including hypertension (HTN). This population-based, nested case–control study analyzed an inception psoriasis cohort from Taiwan's National Health Insurance Research Database between 2000–2010.
Paine and Ritchlin have reviewed the evidence that new bone formation is centered around enthesial sites and that such findings are evident in psoriatic arthritis as well as psoriasis patients without arthritis.
Dr. Peter Taylor and colleagues presented their results of the 52-week BEAM trial wherein baricitinib (a JAK 1, 2 inhibitor) was compared to adalimumab in both clinical and radiographic outcomes. This was the most viewed abstract online at the ACR website.
Cacoub et al review the common entity cryoglobulinemic vasculitis (CryoVas) in the current issue of the American Journal of Medicine.
This small-vessel vasculitis involves the skin, joints, and potentially other organs, including the peripheral nervous system or the kidneys.
Methotrexate is a mainstay drug in the treatment of rheumatoid arthritis (RA). Yet, we may not be using it long enough or optimizing its use.
The American College of Physicians released a position paper exploring factors driving the growth of “concierge” and other “direct patient contracting practices” (DPCPs) and the “limited” evidence on their impact on patient care.
What do you tell your patients who are considering augmentation mammoplasty? Or who question the safety of prior implants?
Furie and coworkers presented the results of a 52-week phase II trial of anifrolumab (ANIFR), a type I interfernon (IFN) receptor antagonist in patients with lupus (SLE).
Clements et al presented the results of their Scleroderma Lung Study II wherein PSS patients with interstitial lung disease were randomized to receive either 3 grams daily of mycopheonolate or 2mg/kg/day of cyclophosphamide.
Liu and coworkers from Boston presented abstract #1213, with data from the NHS II Survey. They examined 93,859 women (without RA) and their dietary data from 1991 to 2011.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.